

116TH CONGRESS  
2D SESSION

# S. 4640

To amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders, which shall also satisfy certain training requirements to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment, and for other purposes.

---

IN THE SENATE OF THE UNITED STATES

SEPTEMBER 22, 2020

Mr. BENNET (for himself and Ms. COLLINS) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

## A BILL

To amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders, which shall also satisfy certain training requirements to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment, and for other purposes.

- 1       *Be it enacted by the Senate and House of Representa-*
- 2       *tives of the United States of America in Congress assembled,*

1     **SECTION 1. SHORT TITLE.**

2         This Act may be cited as the “Medication Access and  
3     Training Expansion Act of 2020” or the “MATE Act of  
4     2020”.

5     **SEC. 2. REQUIRING PRESCRIBERS OF CONTROLLED SUB-**

6                 **STANCES TO COMPLETE TRAINING ON**  
7                 **TREATING AND MANAGING PATIENTS WITH**  
8                 **OPIOID AND OTHER SUBSTANCE USE DIS-**  
9                 **ORDERS.**

10         (a) IN GENERAL.—Section 303 of the Controlled  
11     Substances Act (21 U.S.C. 823) is amended by adding at  
12     the end the following:

13                 “(l) REQUIRED TRAINING FOR PRESCRIBERS ON  
14     TREATING AND MANAGING PATIENTS WITH OPIOID AND  
15     OTHER SUBSTANCE USE DISORDERS.—

16                 “(1) APPLICABILITY.—This subsection ap-  
17     plies—

18                 “(A) to any practitioner who is licensed  
19     under State law to prescribe controlled sub-  
20     stances; and

21                 “(B) beginning with the first registration  
22     or renewal of registration by the practitioner  
23     under this section that occurs on or after the  
24     date that is 90 days after the date of enactment  
25     of the Medication Access and Training Expan-  
26     sion Act of 2020.

1           “(2) TRAINING REQUIRED.—As a condition on  
2 registration under this section to dispense controlled  
3 substances in schedule II, III, IV, or V, the Attorney  
4 General shall require any practitioner described in  
5 paragraph (1)(A) to meet the following conditions:

6           “(A) In the case of a practitioner who is  
7 a physician, the physician shall meet not less  
8 than 1 of the following conditions:

9           “(i) The physician holds a board cer-  
10 tification in addiction psychiatry or addic-  
11 tion medicine from the American Board of  
12 Medical Specialties.

13           “(ii) The physician holds an addiction  
14 certification or board certification from the  
15 American Society of Addiction Medicine or  
16 the American Board of Addiction Medicine.

17           “(iii) The physician holds a board cer-  
18 tification in addiction medicine from the  
19 American Osteopathic Association.

20           “(iv) The physician has completed not  
21 less than 8 hours of training on the treat-  
22 ment and management of patients with  
23 opioid and other substance use disorders  
24 that—

1                         “(I) is provided through class-  
2                         room situations, seminars at profes-  
3                         sional society meetings, electronic  
4                         communication, or other means;

5                         “(II) is provided by the American  
6                         Society of Addiction Medicine, the  
7                         American Academy of Addiction Psy-  
8                         chiatry, the American Medical Asso-  
9                         ciation, the American Osteopathic As-  
10                         sociation, the American Psychiatric  
11                         Association, or another organization  
12                         that the Secretary determines appro-  
13                         priate; and

14                         “(III) includes content relating  
15                         to—

16                         “(aa) opioid maintenance  
17                         and detoxification;

18                         “(bb) the appropriate clin-  
19                         ical use of all drugs approved by  
20                         the Food and Drug Administra-  
21                         tion for the treatment of a sub-  
22                         stance use disorder;

23                         “(cc) initial and periodic pa-  
24                         tient assessments, including sub-  
25                         stance use monitoring;

1                     “(dd) individualized treatment planning, overdose reversal,  
2                     and relapse prevention;

3                     “(ee) counseling and recovery support services;

4                     “(ff) staffing roles and considerations, including bias and  
5                     anti-racism training to reduce racial and ethnic disparities;

6                     “(gg) diversion control; and

7                     “(hh) other best practices, such as addiction prevention, as  
8                     identified by the Secretary after consultation with practitioners  
9                     from a variety of medical specialties and who practice in different  
10                    settings in which controlled substances are prescribed.

11                    “(v) The physician has participated as an investigator in one or more clinical trials leading to the approval of a narcotic drug in schedule III, IV, or V for maintenance or detoxification treatment, as demonstrated by a statement submitted to the

3                         “(vi) The physician has other training  
4                         or experience that the medical licensing  
5                         board of the State where the physician will  
6                         provide maintenance or detoxification  
7                         treatment considers demonstrative of the  
8                         ability of the physician to treat and man-  
9                         age patients with opioid and other sub-  
10                         stance use disorders.

11                         “(vii)(I) The physician has other  
12 training or experience that the Secretary  
13 identifies, in a regulation promulgated in  
14 accordance with subclause (II), as demon-  
15 strative of the ability of the physician to  
16 treat and manage patients with opioid and  
17 other substance use disorders.

18                             “(II)(aa) The Secretary may by regu-  
19                             lation establish criteria for purposes of  
20                             subclause (I).

21                             “(bb) Subject to item (cc), any cri-  
22                             teria established by the Secretary under  
23                             item (aa) shall be effective for a 3-year pe-  
24                             riod.

1                         “(cc) During the 30-day period pre-  
2 ceding the expiration of a 3-year period of  
3 effectiveness of criteria established under  
4 this subclause, the Secretary may extend  
5 the effectiveness of the criteria for an addi-  
6 tional 3-year period by publishing a notice  
7 of the extension in the Federal Register.

8                         “(viii) The physician—

9                         “(I) graduated in good standing  
10 from an accredited school of allopathic  
11 medicine or osteopathic medicine in  
12 the United States during the 5-year  
13 period preceding the date of the first  
14 registration or renewal of registration  
15 by the physician described in para-  
16 graph (1)(B); and

17                         “(II) has successfully completed  
18 a comprehensive allopathic or osteo-  
19 pathic medicine curriculum or accred-  
20 ited medical residency that included—

21                         “(aa) not less than 8 hours  
22 of training on treating and man-  
23 aging patients with opioid and  
24 other substance use disorders;  
25 and

1                         “(bb) at a minimum—  
2                         “(AA) the training de-  
3                         scribed in items (aa)  
4                         through (hh) of clause  
5                         (iv)(III); and  
6                         “(BB) training with re-  
7                         spect to any other best prac-  
8                         tice the Secretary deter-  
9                         mines necessary, which may  
10                         include training on pain  
11                         management, including as-  
12                         essment and appropriate  
13                         use of opioid and non-opioid  
14                         alternatives.

15                         “(B) In the case of a practitioner who is  
16                         not a physician, the practitioner shall meet not  
17                         less than 1 of the following conditions:

18                         “(i) The practitioner has completed  
19                         not less than 8 hours of initial training on  
20                         the topics listed in subparagraph  
21                         (A)(iv)(III) that—

22                         “(I) is provided through class-  
23                         room situations, seminars at profes-  
24                         sional society meetings, electronic  
25                         communication, or other means; and

1                         “(II) is provided by the American  
2                         Society of Addiction Medicine, the  
3                         American Academy of Addiction Psy-  
4                         chiatry, the American Medical Asso-  
5                         ciation, the American Osteopathic As-  
6                         sociation, the American Nurses  
7                         Credentialing Center, the American  
8                         Psychiatric Association, the American  
9                         Association of Nurse Practitioners,  
10                         the American Academy of Physician  
11                         Assistants, or any other organization  
12                         that the Secretary determines appro-  
13                         priate.

14                         “(ii) The practitioner has other train-  
15                         ing or experience that the Secretary identi-  
16                         fies as demonstrative of the ability of the  
17                         practitioner to treat and manage patients  
18                         with opioid and other substance use dis-  
19                         orders.

20                         “(iii) The practitioner—

21                         “(I) graduated in good standing  
22                         from an accredited physician assistant  
23                         school or school of advanced practice  
24                         nursing in the United States during  
25                         the 5-year period immediately pre-

1 ceding the date of the first registration  
2 or renewal of registration by the  
3 practitioner described in paragraph  
4 (1)(B); and

5 “(II) has successfully completed  
6 a comprehensive physician assistant  
7 or advanced practice nursing curriculum that includes—

9 “(aa) not less than 8 hours  
10 of training on treating and managing  
11 patients with opioid and other substance use disorders;  
12 and

13 “(bb) at a minimum—

14 “(AA) the training described in items (aa)  
15 through (hh) of subparagraph (A)(iv)(III); and

16 “(BB) training with respect to any other best practice the Secretary determines necessary, which may include training on pain management, including assessment and appropriate

use of opioid and non-opioid alternatives.

### 3            "(3) RECIPROCAL TREATMENT.—

4                           “(A) PHYSICIANS.—

5                         “(i) MEETING CONDITIONS FOR PRE-  
6                         SCRIBING.—A physician who meets one or  
7                         more of the conditions listed in paragraph  
8                         (2)(A) shall be deemed to meet one or  
9                         more of the conditions listed in subsection  
0                         (g)(2)(G)(ii).

“(ii) MEETING CONDITIONS FOR  
WAIVER FOR DISPENSING.—A physician  
who meets one or more of the conditions  
listed in subsection (g)(2)(G)(ii) shall be  
deemed to meet one or more of the condi-  
tions listed in paragraph (2)(A).

17                   “(B) OTHER PRACTITIONERS.—

18                             “(i) MEETING CONDITIONS FOR PRE-  
19                             SCRIBING.—A practitioner who is not a  
20                             physician, and who meets one or more of  
21                             the conditions listed in paragraph (2)(B),  
22                             shall be deemed to meet one or more of the  
23                             conditions listed in subsection  
24                             (g)(2)(G)(iv)(II).

1                         “(ii) MEETING CONDITIONS FOR  
2                         WAIVER FOR DISPENSING.—A practitioner  
3                         who is not a physician, and who meets one  
4                         or more of the conditions listed in sub-  
5                         section (g)(2)(G)(iv)(II), shall be deemed  
6                         to meet one or more of the conditions list-  
7                         ed in paragraph (2)(B).”.

8                         (b) TRAINING REQUIRED.—

9                         (1) PHYSICIANS.—Section  
10                         303(g)(2)(G)(ii)(IV)(hh) of the Controlled Sub-  
11                         stances Act (21 U.S.C. 823(g)(2)(G)(ii)(IV)(hh)) is  
12                         amended by inserting after “, as identified by the  
13                         Secretary” the following: “, which may include best  
14                         practices for addiction prevention”.

15                         (2) OTHER PRACTITIONERS.—Section  
16                         303(g)(2)(G)(iv)(II) of the Controlled Substances  
17                         Act (21 U.S.C. 823(g)(2)(G)(iv)(II)) is amended—

18                         (A) in item (aa), by striking “or” at the  
19                         end;

20                         (B) in item (bb), by striking the period at  
21                         the end and inserting “; or”; and

22                         (C) by adding at the end the following:

23                         “(cc) graduated in good standing from an  
24                         accredited physician assistant school or school  
25                         of advanced practice nursing in the United

1           States during the 5-year period immediately  
2           preceding the date on which the practitioner  
3           submits to the Secretary a notification under  
4           subparagraph (B) and has successfully com-  
5           pleted a comprehensive physician assistant or  
6           advanced practice nursing curriculum that in-  
7           cludes—

8                 “(AA) not less than 8 hours of train-  
9                 ing on treating and managing opioid-de-  
10                pendent patients;

11                 “(BB) the training described in items  
12                 (aa) through (hh) of clause (ii)(IV); and

13                 “(CC) training with respect to any  
14                 other best practice the Secretary deter-  
15                 mines necessary, which may include train-  
16                 ing on pain management, including assess-  
17                 ment and appropriate use of opioid and  
18                 non-opioid alternatives.”.

19                 (3) TECHNICAL CORRECTIONS.—Section  
20                 303(g)(2)(G) of the Controlled Substances Act (21  
21                 U.S.C. 823(g)(2)(G)) is amended—

22                     (A) in clause (ii)—

23                         (i) by moving subclauses (I) and (II)  
24                         4 ems to the left;

25                         (ii) in subclause (VIII)—

○